Lactobacillus improves IBS-C symptomsClinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink.
Consistent findings support treatment benefit
We investigated how a cultured milk drink containing Lactobacillus acidophilus affects symptoms of constipation in individuals with irritable bowel syndrome (IBS-C). Over 30 days, participants consumed the drink daily.
At the end of the study, an impressive 97.4% of IBS-C participants reported improvement in their constipation-related symptoms. We also noticed reductions in intestinal transit time and pro-inflammatory cytokines linked to IBS. Overall, this suggests that including this cultured milk drink may be a beneficial addition to IBS-C treatment plans.
Read More
Probiotics improve constipation symptomsImpact of a probiotic chewable tablet on stool habits and microbial profile in children with functional constipation: A randomized controlled clinical trial.
High relevance to childhood constipation.
We conducted a randomized, placebo-controlled trial involving 92 children aged 4 to 12 with functional constipation. Over four weeks, we provided one group with a probiotic chewable tablet containing specific strains and compared their experiences to a placebo group.
The findings were promising; the probiotic group reported a significant improvement in stool frequency and a decrease in hard defecation. Specifically, hard stools decreased from 43% to 14%, while normal defecation increased from 56% to 80%. This study highlights the potential of probiotics as a valuable option for managing constipation in children.
Read More
We evaluated how lactobacillus acidophilus, both alone and in a mix with other bacteria, might relieve constipation caused by loperamide in rats. Over 14 days, we noticed that the groups receiving probiotics had significantly heavier and wetter stools compared to control animals.
Notably, the CKDBP group, a blend of multiple bacteria, showed the greatest improvement in intestinal transit. Measures like mucosal length and mucus secretion were also significantly enhanced in all probiotic-treated groups, highlighting their potential to alleviate constipation symptoms effectively.
Read More
We investigated the impact of Bifidobacterium animalis subsp. lactis XLTG11 on functional constipation in children using a randomized, double-blind, placebo-controlled design.
Our findings showed that children receiving this probiotic experienced a significant increase in their weekly fecal frequency compared to those on conventional treatment without probiotics.
Additionally, the introduction of XLTG11 altered gut microbiota positively and influenced the metabolism of short-chain fatty acids. These results suggest that Bifidobacterium can benefit children suffering from constipation.
Read More
We explored the effectiveness of Bifidobacterium longum W11 in treating constipation, particularly in patients with irritable bowel syndrome (IBS). Our research included rigorous reviews and clinical trials, one of which was randomized and placebo-controlled.
The findings were promising—B. longum W11 significantly reduced constipation symptoms, especially in those experiencing reduced gut motility due to calorie-restricted diets.
Additionally, its non-transmissible antibiotic resistance may offer advantages when used alongside antibiotics like rifaximin, showing improved outcomes in certain conditions like diverticular disease.
Read More